Inherited Metabolic Disorders
Discover unique market-leading data and insights into the Inherited Metabolic Disorders market. From the latest Inherited Metabolic Disorders industry reports and analysis to comprehensive market growth forecasts, trends and research.
Browse our full list of Inherited Metabolic Disordersmarket reports here.
- Currency Conversion is for Indicative purpose only. All orders are processed in US Dollars only.
- USD - US Dollar
- AUD — Australian Dollar
- BRL — Brazilian Real
- CNY — Yuan Renminbi
- EUR — Euro
- GBP — Pound Sterling
- INR — Indian Rupee
- JPY — Japanese Yen
- ZAR — South African Rand
- The Price Conversion is only for the Indicative purpose.
- USD — US Dollar
- AUD — Australian Dollar
- BRL — Brazilian Real
- CNY — Yuan Renminbi
- EUR — Euro
- GBP — Pound Sterling
- INR — Indian Rupee
- JPY — Japanese Yen
- ZAR — South African Rand
-
Product Insights
Product Insights Glycogen Storage Disorders (GSD) – Drugs In Development, 2023 Glycogen Storage Disorders (GSD) – Drugs In Development, 2023
$2,000 | January 2024 Global Markets Direct’s, ‘Glycogen Storage Disorders (GSD) - Drugs In Development, 2023’, provides an overview of the Glycogen Storage Disorders (GSD) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Glycogen Storage Disorders (GSD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Product Insights Inherited Mitochondrial Disorders – Drugs In Development, 2023 Inherited Mitochondrial Disorders – Drugs In Development, 2023
$2,000 | January 2024 Global Markets Direct’s, ‘Inherited Mitochondrial Disorders - Drugs In Development, 2023’, provides an overview of the Inherited Mitochondrial Disorders pipeline landscape. The report provides comprehensive information on the therapeutics under development for Inherited Mitochondrial Disorders, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Product Insights Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) – Drugs In Development, 2023 Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) – Drugs In Development, 2023
$2,000 | January 2024 Global Markets Direct’s, ‘Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) - Drugs In Development, 2023’, provides an overview of the Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Product Insights Gaucher Disease Type I – Drugs In Development, 2023 Gaucher Disease Type I – Drugs In Development, 2023
$2,000 | January 2024 Global Markets Direct’s, ‘Gaucher Disease Type I - Drugs In Development, 2023’, provides an overview of the Gaucher Disease Type I pipeline landscape. The report provides comprehensive information on the therapeutics under development for Gaucher Disease Type I, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Product Insights Subacute Necrotizing Encephalomyelopathy (Leigh Disease) – Drugs In Development, 2023 Subacute Necrotizing Encephalomyelopathy (Leigh Disease) – Drugs In Development, 2023
$2,000 | January 2024 Global Markets Direct’s, ‘Subacute Necrotizing Encephalomyelopathy (Leigh Disease) - Drugs In Development, 2023’, provides an overview of the Subacute Necrotizing Encephalomyelopathy (Leigh Disease) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Subacute Necrotizing Encephalomyelopathy (Leigh Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Product Insights Ornithine-Transcarbamylase Deficiency – Drugs In Development, 2023 Ornithine-Transcarbamylase Deficiency – Drugs In Development, 2023
$2,000 | January 2024 Global Markets Direct’s, ‘Ornithine-Transcarbamylase Deficiency - Drugs In Development, 2023’, provides an overview of the Ornithine-Transcarbamylase Deficiency pipeline landscape. The report provides comprehensive information on the therapeutics under development for Ornithine-Transcarbamylase Deficiency, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Product Insights Glycogen Storage Disease 1A – Drugs In Development, 2023 Glycogen Storage Disease 1A – Drugs In Development, 2023
$2,000 | January 2024 Global Markets Direct’s, ‘Glycogen Storage Disease 1A - Drugs In Development, 2023’, provides an overview of the Glycogen Storage Disease 1A pipeline landscape. The report provides comprehensive information on the therapeutics under development for Glycogen Storage Disease 1A, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Product Insights Adrenomyeloneuropathy (AMN) – Drugs In Development, 2023 Adrenomyeloneuropathy (AMN) – Drugs In Development, 2023
$2,000 | January 2024 Global Markets Direct’s, ‘Adrenomyeloneuropathy (AMN) - Drugs In Development, 2023’, provides an overview of the Adrenomyeloneuropathy (AMN) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Adrenomyeloneuropathy (AMN), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Product Insights Gaucher Disease Type III – Drugs In Development, 2023 Gaucher Disease Type III – Drugs In Development, 2023
$2,000 | January 2024 Global Markets Direct’s, ‘Gaucher Disease Type III - Drugs In Development, 2023’, provides an overview of the Gaucher Disease Type III pipeline landscape. The report provides comprehensive information on the therapeutics under development for Gaucher Disease Type III, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Product Insights Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) – Drugs In Development, 2023 Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) – Drugs In Development, 2023
$2,000 | January 2024 Global Markets Direct’s, ‘Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) - Drugs In Development, 2023’, provides an overview of the Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.